its application for marketing authorization of pertuzumab injection has been accepted.
November 13, 2025
Source: drugdu
73
On November 12, CSPC Pharmaceutical Group (01093) issued an announcement stating that the marketing application of pertuzumab injection developed by its subsidiary, CSPC Jushi Biopharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration.
This product is a recombinant humanized anti-HER2 monoclonal antibody injection, mainly used to treat HER2-positive breast cancer. The product has good safety and tolerability, comparable to the original reference drug.
https://finance.eastmoney.com/a/202511123562408428.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
